Caricamento quotazioni...
Previsioni
| Acquista |
2 |
| Mantieni |
0 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
InMed Pharmaceuticals meets NASDAQ minimum bid-price requirement again
NASDAQ said InMed Pharmaceuticals has met the listing requirement after the closing price of its common stock was at or above $1.00 for ten consecutive trading days from May 19 through last Monday. The exchange has closed the matter; the stock currently trades at $1.56 and, despite a 50% year-to-date increase, remains well below the 52-week high of $5.50. InMed has a market capitalization of $6.96 million and is developing small-molecule drug candidates targeting CB1/CB2 receptors with programs for Alzheimer’s, eye diseases and dermatology. » Altro su de.investing.com
InMed Pharmaceuticals files prospectus supplement for at-the-market offering
InMed Pharmaceuticals has filed a prospectus supplement and the related prospectus with the U.S. securities regulator SEC for the sale of common shares under an existing at-the-market agreement with H.C. Wainwright & Co. The filing relies on the S-3 shelf registration that the SEC declared effective on March 30, 2026. The supplement includes a legal opinion from Norton Rose Fulbright Canada LLP on the validity of the offered securities. » Altro su de.investing.com
InMed Pharmaceuticals faces delisting after falling below Nasdaq minimum bid price
InMed Pharmaceuticals received a notice from Nasdaq because the stock’s closing price was below $1.00 for 30 consecutive trading days between Feb. 11 and Mar. 26, 2026. The shares currently trade at $0.66 with a market capitalization of $2.59 million; InMed has 180 calendar days to cure the deficiency by achieving a closing price of at least $1.00 for ten consecutive trading days. If the company does not comply, a one-time extension is possible; otherwise delisting is threatened, with a possible appeal to the Nasdaq Hearings Panel. InMed is evaluating options such as a reverse stock split and will monitor the share price. » Altro su de.investing.com
InMed Pharmaceuticals reports quarterly loss of $0.43 per share and moderate revenue increase
InMed Pharmaceuticals released results for the quarter ended June 30, 2025: loss per share was $0.43 compared with -$3.80 in the year-ago quarter. Quarterly revenue was $1.3 million (+1.56% year on year). For the full year, loss per share narrowed to $8.36 (prior year -$20.20) on revenue of $4.94 million (+7.39% year on year). » Altro su finanzen.net
InMed Pharmaceuticals sets date and record date for 2025 annual general meeting
InMed Pharmaceuticals announced the date, record date and organizational details for its 2025 annual general meeting and filed the information on SEDAR and in a Form 8‑K with the SEC. The company gave no information on agenda items or proposals. It is registered in British Columbia, headquartered in Vancouver; its common shares trade on NASDAQ under the ticker INM; market capitalization is about 4.31 million USD and the stock is down more than 52% year-to-date. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 0 | 100,00% |
| Utile lordo | -195,14K | 156,80% |
| Utile netto | -2,06 Mln | 39,83% |
| EBITDA | -1,58 Mln | 18,09% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 7,77 Mln € |
Numero di azioni | 549,37K |
Massimo/minimo a 52 settimane | 21,19 € - 5,23 € |
| Dividendi | No |
Beta | 0,99 |
Rapporto P/E | -0,60 |
Rapporto PEG | -0,01 |
Rapporto P/B | -8,48 |
Rapporto P/S | 0,00 |
Profilo aziendale
InMed Pharmaceuticals Inc., una società farmaceutica in fase di sviluppo clinico, svolge attività di ricerca e sviluppo di terapie a base di cannabinoidi. Il prodotto di punta della società è INM-755, una crema topica al cannabinolo, che si trova in una seconda sperimentazione clinica di Fase I per il trattamento dell'epidermolisi bullosa. La società è inoltre impegnata nello sviluppo di INM-088, in fase di studi preclinici per il trattamento del glaucoma; e di INM-405 per il trattamento del dolore. Inoltre, si occupa dello sviluppo di trattamenti a base di cannabinoidi per varie malattie, tra cui le patologie dermatologiche e oculari. Inoltre, la società lavora su studi di farmacologia e tossicologia preclinica abilitanti per la domanda IND; e su IntegraSyn, un approccio integrato di produzione basato sulla biosintesi, per la sintesi di cannabinoidi di grado farmaceutico. Ha un accordo di collaborazione di ricerca con BayMedica Inc. per la produzione e il test di nuove terapie a base di cannabinoidi. La società era precedentemente nota come Cannabis Technologies Inc. e ha cambiato denominazione in InMed Pharmaceuticals Inc. nell'ottobre 2014. InMed Pharmaceuticals Inc. è stata costituita nel 1981 ed ha sede a Vancouver, in Canada.
| Nome | InMed Pharmaceuticals |
| CEO | Eric A. Adams Chem. |
| Sede centrale | Vancouver,
bc Canada |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 05/05/2014 |
| Dipendenti | 6 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | INM |
Frankfurt | MWG.F |